• MTO_Title
  • In Vivo Nanoplatforms (IVN)

    Disease limits soldier readiness and creates healthcare costs and logistics burdens. Diagnosing and treating disease faster can help limit its impact. Current technologies and products for diagnosing disease are principally relegated to in vitro (in the lab) medical devices, which are often expensive, bulky and fragile.

    Disease limits soldier readiness and creates healthcare costs and logistics burdens. Diagnosing and treating disease faster can help limit its impact. Current technologies and products for diagnosing disease are principally relegated to in vitro (in the lab) medical devices, which are often expensive, bulky and fragile.

    DARPA’s In Vivo Nanoplatforms (IVN) program seeks to develop new classes of adaptable nanoparticles for persistent, distributed, unobtrusive physiologic and environmental sensing as well as the treatment of physiologic abnormalities, illness, and infectious disease.

    The IVN Diagnostics (IVN:Dx) program effort aims to develop a generalized in vivo platform that provides continuous physiological monitoring for the warfighter. Specifically, IVN:Dx investigates technologies that provide:

    • Implantable nanoplatforms using bio-compatible and nontoxic materials
    • In vivo sensing of small and large molecules of biological interest
    • Multiplexed detection of analytes at clinically relevant concentrations
    • External interrogation of the nanoplatform free from any implanted communications electronics

    The IVN Therapeutics (IVN:Tx) program effort seeks unobtrusive nanoplatforms for rapidly treating disease in warfighters. This program aims to develop nanotherapeutics that:

    • Increase safety and minimize the dose required for clinically relevant efficacy
    • Limit off-target effects
    • Limit immunogenicity
    • Increase effectiveness by targeting delivery to specific tissues and/or uptake by cells of interest
    • Increase bioavailability
    • Knock down medically relevant molecular target(s)
    • Increase resistance to degradation

    Successful nanotherapeutic platforms should enable treatment of military-relevant diseases such as infections caused by multi-drug resistant organisms and conditions due to traumatic brain injury.

    The IVN:Dx program began in Winter, 2012. The IVN:Tx program began in Spring, 2013.

Share this page: